Page 109 - 《中国药房》2024年6期
P. 109

奥司他韦、扎那米韦和玛巴洛沙韦的不良事件信号挖掘与分析
                                                                                                         Δ


                                               #
          蒋婷婷 ,张 妮,苏 辉,李艳平,刘 耀(陆军军医大学大坪医院药剂科,重庆 400042)
                *
          中图分类号  R969.3      文献标志码  A      文章编号  1001-0408(2024)06-0739-05
          DOI  10.6039/j.issn.1001-0408.2024.06.18

          摘  要  目的  挖掘3种抗甲型流感病毒药物(奥司他韦、扎那米韦、玛巴洛沙韦)的不良事件(ADE)信号,为临床安全用药提供参
          考。方法  收集美国FDA不良事件报告系统(FAERS)2004年第1季度至2022年第3季度上报的奥司他韦、扎那米韦、玛巴洛沙韦
          ADE数据,采用报告比值比(ROR)法进行数据挖掘,评估指定医疗事件(DME),利用《国际医学用语词典》(25.0版)药物ADE术
          语集中的系统器官分类(SOC)进行分类统计。结果  分别检索到奥司他韦、扎那米韦、玛巴洛沙韦ADE报告12 636、1 749、1 283
          例,分别累及26、16、17个SOC。奥司他韦与睡惊症、异常行为、幻觉、谵妄的关联性较强;扎那米韦涉及的异常行为、谵妄、语无伦
          次、意识状态改变信号强度突出;玛巴洛沙韦与缺血性结肠炎、出血性膀胱炎、多形性红斑、黑便的关联性较强。3种药物的DME
          均检出多形性红斑,且信号较强。结论  临床应用奥司他韦等3种药物时,除关注常见ADE外,还应加强关注药品说明书中未提及
          的 ADE。对于奥司他韦应警惕急性肾损伤、暴发性肝炎,定期监测患者的肝肾功能;对于扎那米韦应警惕与呼吸系统相关的
          ADE,包括急性呼吸窘迫综合征、呼吸衰竭,并密切关注患者的呼吸状况;对于玛巴洛沙韦应警惕多形性红斑、横纹肌溶解等
          ADE。
          关键词  抗甲型流感病毒药物;奥司他韦;扎那米韦;玛巴洛沙韦;信号挖掘;不良事件

          Signal mining and analysis of adverse events of oseltamivir, zanamivir and baloxavir marboxil
          JIANG Tingting,ZHANG Ni,SU Hui,LI Yanping,LIU Yao(Department  of  Pharmacy,  Daping  Hospital, Army
          Medical University, Chongqing 400042, China)

          ABSTRACT   OBJECTIVE To provide reference for safe drug use in clinic by mining the adverse drug events (ADE) of 3 kinds
          of anti-influenza A virus drugs (oseltamivir, zanamivir, baloxavir marboxil). METHODS The ADE data of oseltamivir, zanamivir
          and baloxavir marboxil were collected from the FDA adverse event reporting system (FAERS) between the first quarter in 2004 and
          the  third  quarter  in  2022,  and  mined  by  using  reporting  odds  ratio (ROR)  method.  The  designated  medical  events (DME)  were
          estimated.  The  system  organ  class (SOC)  in  the  Medical  Dictionary  for  Regulatory  Activities (MedDRA,  version  25.0)  was  used
          for  the  classification  and  statistics  of  drug ADE  terminology.  RESULTS  A  total  of  12  636,  1  749  and  1  283 ADE  reports  were
          retrieved for oseltamivir, zanamivir and baloxavir marboxil, involving 26, 16 and 17 SOCs, respectively. Oseltamivir was strongly
          associated  with  sleep  terror,  abnormal  behavior,  hallucination  and  delirium.  Zanamivir  was  implicated  in  abnormal  behavior,
          delirium,  incoherence,  and  altered  state  of  consciousness  with  prominent  signal  intensity.  Baloxavir  marboxil  was  strongly
          associated  with  ischemic  colitis,  hemorrhagic  cystitis,  erythema  multiforme  and  melaena.  Erythema  multiform  was  detected  in  the
          DME of three drugs with strong signals. CONCLUSIONS When clinically administering the three drugs, it is crucial to pay close
          attention  to  both  common  adverse  reactions  and  those  ADEs  that  are  not  explicitly  mentioned  in  the  drug  instructions.  For
          oseltamivir, clinicians should exercise caution due to the potential risk of acute kidney injury and fulminant hepatitis, necessitating
          regular monitoring of the patient’s liver and kidney function. When prescribing zanamivir, caution should be exercised due to ADEs
          related  to  the  respiratory  system,  including  acute  respiratory  distress  syndrome  and  respiratory  failure,  necessitating  close
          monitoring  of  the  patient’s  respiratory  status.  Similarly,  for  baloxavir  marboxil,  clinicians  should  be  vigilant  for  potential  ADEs
          such as erythema multiforme and rhabdomyolysis.
          KEYWORDS    anti-influenza A virus drug; oseltamivir; zanamivir; baloxavir marboxil; signal mining; adverse drug event



              甲型流感病毒是流行性感冒的主要病原体之一,其                         甲型流感病毒的治疗主要以抗病毒为主,国内常用的抗
          传播速度快、传染性强,每年约7亿人感染,导致近60万                         甲型流感病毒药物主要分为两类:第一类是神经氨酸酶
                                                 [1]
          人死亡,已成为人类面临的重大公共卫生问题 。目前,                          抑制剂,如奥司他韦、扎那米韦,该类药物可通过选择性
             Δ 基金项目 重庆市技术创新与应用发展专项重点项目(No.                   结合神经氨酸酶而阻止病毒释放,是治疗甲型流感病毒
          CSTC2021jscx-gksb-N0013);重庆市中青年医学高端人才项目            的首选药物 ;第二类是 RNA 聚合酶抑制剂,如玛巴洛
                                                                       [2]
             *第一作者 药师,硕士。研究方向:医院药学、药物警戒。E-mail:
                                                             沙韦,该药于 2021 年在我国批准上市,主要作用于病毒
          jiangtt0817@163.com
                                                             的 RNA 聚合酶,可抑制病毒复制            [3―4] 。药物的安全性评
             # 通信作者 副主任药师,博士。研究方向:临床药学、药事管理、
          药物警戒。E-mail:swhliuyao@163.com                      价是一个持续的过程,虽然奥司他韦、扎那米韦在我国

          中国药房  2024年第35卷第6期                                                 China Pharmacy  2024 Vol. 35  No. 6    · 739 ·
   104   105   106   107   108   109   110   111   112   113   114